Results 51 to 60 of about 1,194,407 (281)

Acute myeloid leukemia: Comparing French–American–British classification with immunophenotype and cytogenetics

BLDE University Journal of Health Sciences, 2022
BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease as it affects multiple lineages of hematopoietic cells. AIMS AND OBJECTIVES: This study aims to (1) evaluate the immunophenotypic findings of AML patients, (2) correlate the ...
Mekhala Rao, Girish Kamat, Deepak Goni, Girish Balikai   +3 more
doaj   +1 more source

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52).

Clinical Microbiology and Infection, 2018
BACKGROUND The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies.
M. Mikulska, S. Lanini, Carlota Gudiol, Ľ. Drgoňa, Giuseppe Ippolito, Mario Fernández-Ruiz, Mario Fernández-Ruiz, B. Salzberger   +7 more
semanticscholar   +1 more source

Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on immune responses to schistosome antigens among the offspring: results of a randomised, placebo-controlled trial. [PDF]

, 2011
BACKGROUND: Offspring of women with schistosomiasis may exhibit immune responsiveness to schistosomes due to in utero sensitisation or trans-placental transfer of antibodies.
Webb, Emily L, Emily L Webb, Dunne, David W, Dunne, David W., Tweyongyere, Robert, Mawa, Patrice A, Birgitte J Vennervald, David W Dunne, Jones, Frances M., Webb, Emily L., Elliott, Alison M., Patrice A Mawa, Vennervald, Birgitte J, Frances M Jones, Stephen Cose, Kihembo, Macklyn, Alison M Elliott, Cose, Stephen, Macklyn Kihembo, Elliott, Alison M, Robert Tweyongyere, Jones, Frances M, Mawa, Patrice A.   +22 more
core   +1 more source

Unifying heterogeneous expression data to predict targets for CAR-T cell therapy

OncoImmunology, 2021
Chimeric antigen receptor (CAR) T-cell therapy combines antigen-specific properties of monoclonal antibodies with the lytic capacity of T cells. An effective and safe CAR-T cell therapy strategy relies on identifying an antigen that has high expression ...
Patrick Schreiner, Mireya Paulina Velasquez, Stephen Gottschalk, Jinghui Zhang, Yiping Fan   +4 more
doaj   +1 more source

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Nature Medicine, 2018
Tolerance to self-antigens prevents the elimination of cancer by the immune system1,2. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL).
J. Fraietta, S. Lacey, Elena J Orlando, Iulian Pruteanu-Malinici, M. Gohil, Stefan Lundh, A. Boesteanu, Yan Wang, Roddy S. O’Connor, W. Hwang, E. Pequignot, David E. Ambrose, Changfeng Zhang, Nicholas Wilcox, Felipe Bedoya, C. Dorfmeier, Fang Chen, Lifeng Tian, Harit Parakandi, Minnal Gupta, Regina M. Young, F. B. Johnson, I. Kulikovskaya, Li Liu, Jun Xu, Sadik H. Kassim, M. Davis, B. Levine, N. Frey, D. Siegel, Alexander C. Huang, E. Wherry, H. Bitter, J. Brogdon, D. Porter, C. June, J. Melenhorst   +36 more
semanticscholar   +1 more source

Efficacy of Dual Cd19-Cd79B Car In B-Cell Malignancies [PDF]

, 2022
Despite high clinical responses, about 30%-60% of patients with B-cell malignancies relapse following CD19-targeting chimeric antigen receptor (CAR) T cell therapy. CD19 loss is a major cause of relapse and resistance after CD19 CAR T therapy.
Cheng, Xiaoyun
core   +1 more source

Abstract 3768: CAR T cells specific for CD19 can be redirected to kill CD19 negative tumors [PDF]

, 2017
Introduction. Remarkable progress has been made in the treatment of relapsed/refractory Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma with CAR-CD19 T cells. In contrast, progress against CD19-negative hematological cancers and solid tumors has been
Paul D. Rennert, Lihe Su, Christine Ambrose, Lan Wu, Roy R. Lobb   +4 more
core   +1 more source

Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells

Science Translational Medicine, 2016
A CD19 chimeric antigen receptor–modified T cell product with defined composition has potent antitumor activity. Standardizing the CAR assembly line Chimeric antigen receptor (CAR)–modified T cells are engineered to recognize specific tumor antigens ...
C. Turtle, L. Hanafi, C. Berger, M. Hudecek, B. Pender, E. Robinson, R. Hawkins, Colette N. Chaney, S. Cherian, Xueyan Chen, L. Soma, B. Wood, Daniel H. Li, S. Heimfeld, S. Riddell, D. Maloney   +15 more
semanticscholar   +1 more source

Chimeric antigen receptor–modified T cells: CD19 and the road beyond [PDF]

Blood, 2018
Abstract The ability to harness a patient’s immune system to target malignant cells is now transforming the treatment of many cancers, including hematologic malignancies. The adoptive transfer of T cells selected for tumor reactivity or engineered with natural or synthetic receptors has emerged as an effective modality, even for patients
Alexander I. Salter, Margot J. Pont, Stanley R. Riddell   +2 more
openaire   +2 more sources

The CD19/CD21 Complex Functions to Prolong B Cell Antigen Receptor Signaling from Lipid Rafts [PDF]

, 2001
The CD19/CD21 complex functions to significantly enhance B cell antigen receptor (BCR) signaling in response to complement-tagged antigens. Recent studies showed that following antigen binding the BCR translocates into plasma membrane lipid rafts that ...
Paul C. Cheng, Cherukuri, Anu, Cheng, Paul C., Susan K. Pierce, Pierce, Susan K., Sohn, Hae Won, Anu Cherukuri, Hae Won Sohn   +7 more
core   +1 more source